BR9611157A - Derivados de purina e processos para sua preparação - Google Patents

Derivados de purina e processos para sua preparação

Info

Publication number
BR9611157A
BR9611157A BR9611157A BR9611157A BR9611157A BR 9611157 A BR9611157 A BR 9611157A BR 9611157 A BR9611157 A BR 9611157A BR 9611157 A BR9611157 A BR 9611157A BR 9611157 A BR9611157 A BR 9611157A
Authority
BR
Brazil
Prior art keywords
processes
preparation
purine derivatives
purine
derivatives
Prior art date
Application number
BR9611157A
Other languages
English (en)
Portuguese (pt)
Inventor
Juerg Zimmermann
Hans-Georg Capraro
Patricia Imbach
Pascal Furet
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9611157A publication Critical patent/BR9611157A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9611157A 1995-11-01 1996-10-22 Derivados de purina e processos para sua preparação BR9611157A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH309495 1995-11-01
CH221396 1996-09-10
PCT/EP1996/004573 WO1997016452A1 (en) 1995-11-01 1996-10-22 Purine derivatives and processes for their preparation

Publications (1)

Publication Number Publication Date
BR9611157A true BR9611157A (pt) 1999-03-30

Family

ID=25689809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611157A BR9611157A (pt) 1995-11-01 1996-10-22 Derivados de purina e processos para sua preparação

Country Status (13)

Country Link
US (1) US7091346B1 (https=)
EP (1) EP0874846B1 (https=)
JP (2) JP4004066B2 (https=)
CN (1) CN1066147C (https=)
AR (1) AR004134A1 (https=)
AT (1) ATE236161T1 (https=)
AU (1) AU7296896A (https=)
BR (1) BR9611157A (https=)
CA (1) CA2234609C (https=)
DE (1) DE69627195T2 (https=)
ES (1) ES2196181T3 (https=)
PT (1) PT874846E (https=)
WO (1) WO1997016452A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CA2297967A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
NZ503788A (en) 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
AU1631699A (en) * 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
DE69912248T2 (de) * 1998-02-26 2004-04-22 Aventis Pharmaceuticals Inc. 6,9-disubstituierte 2-[trans-(4-aminocyclohexyl)amino] purine
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
IL138044A0 (en) * 1998-02-26 2001-10-31 Aventis Pharma Inc 6,9-disubstituted 2-[trans- 4-aminocyclohexyl) amino] purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
ATE322494T1 (de) * 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1399446B1 (en) 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
AR041292A1 (es) 2002-09-19 2005-05-11 Schering Corp Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
EP2132208A1 (en) * 2007-03-28 2009-12-16 NeuroSearch AS Purinyl derivatives and their use as potassium channel modulators
JP2010522719A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
BR112013023050A8 (pt) 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN105283206B (zh) * 2013-03-27 2019-11-08 财团法人峨山社会福祉财团 包含p34的表达抑制剂或活性抑制剂作为有效成分的用于治疗或转移抑制癌的组合物
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
AU626983B2 (en) 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
EP0625158B1 (en) * 1992-01-06 1999-03-31 The Wellcome Foundation Limited Therapeutic nucleosides of the 2',3'-dideoxy-3'-fluoro-purine series
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis

Also Published As

Publication number Publication date
WO1997016452A1 (en) 1997-05-09
US7091346B1 (en) 2006-08-15
JP4004066B2 (ja) 2007-11-07
CN1066147C (zh) 2001-05-23
ES2196181T3 (es) 2003-12-16
AU7296896A (en) 1997-05-22
CA2234609A1 (en) 1997-05-09
CN1202896A (zh) 1998-12-23
DE69627195D1 (de) 2003-05-08
EP0874846A1 (en) 1998-11-04
JP2007231023A (ja) 2007-09-13
AR004134A1 (es) 1998-09-30
ATE236161T1 (de) 2003-04-15
EP0874846B1 (en) 2003-04-02
DE69627195T2 (de) 2004-01-29
JPH11514336A (ja) 1999-12-07
CA2234609C (en) 2006-11-28
PT874846E (pt) 2003-08-29
HK1016580A1 (en) 1999-11-05

Similar Documents

Publication Publication Date Title
BR9611157A (pt) Derivados de purina e processos para sua preparação
BR9605919A (pt) Catalisadores e processos para sua preparação
PT1015444E (pt) Derivados de pirimidina e processos para a sua preparacao
DE69637657D1 (de) Klient-Server-System
HUP9801836A2 (hu) Guaninszármazékok és eljárás ezek előállítására
BR9606396A (pt) Derivados de camptotecin substituídos e processo para sua preparação
BR9408463A (pt) Novos derivados de ginkgolide e processo para sua preparação
DE19681549T1 (de) Strukturmeßsystem
BR9505940A (pt) Comprimido mastigável e processo para sua preparação
DE69615811D1 (de) Abbildungssystem
NO975977D0 (no) Substituerte purinderivater, fremgangsmåter for fremstilling og anvendelse derav
BR9602983A (pt) Gel e processo para sua preparação
BR9605702A (pt) Alourante para cabelos humanos
BR9507494A (pt) Processo para a preparação de famciclovi de 2-amino-6-cloro purina e processo para a preparação de penciclovi de 2-amino-6- cloro purina
DE69637653D1 (de) Bilderzeugungssystem
BR9600149A (pt) 2-(2-N-alcoxifenil)-purin-6-onas 9-substituídas processo para sua preparação medicamantos e uso
DE69636491D1 (de) Bilderzeugungssystem
DE69533584D1 (de) Klinische Nährungszusammensetzung
BR9610674A (pt) Método para extensão de pigmentos
BR9602779A (pt) Cis-n-propenil-acetamidas n-substituídas processo para sua preparação e uso
BR9708461A (pt) Derivados de butadieno e processos para sua preparação
BR9610251A (pt) Compostos de amidopropil-n-alquil-poli-hidroxialquilamina processos para sua preparação e sua aplicação
FI953181A7 (fi) Puriinien valmistusmenetelmä
BR9602729A (pt) Oxafosforina e processo para sua preparação
ZA969168B (en) Purine derivatives and processes for their preparation

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTIGOS 24 E 25 DA LPI.